Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Classical hematology 1

Conditions

Mucositis 3Hematologic Neoplasms 3Thrombocytopenia 1Sarcoma 1Ovarian Neoplasms 1Osteosarcoma 1Neutropenia 1Multiple Myeloma 1Lymphopenia 1Lymphoma, Non-Hodgkin 1Hodgkin Disease 1Graft vs Host Disease 1Cytopenia 1Chondrosarcoma 1Bone Neoplasms 1Anemia 1

Interventions

Paclitaxel 134Carboplatin 129Bevacizumab 86Gemcitabine 45pembrolizumab 37olaparib 33Cisplatin 30liposomal doxorubicin 29Docetaxel 29Cyclophosphamide 29Topotecan 28niraparib 27Taxes 20Etoposide 18Filgrastim 16Doxorubicin 16Immunoglobulin G 15Disulfides 15apatinib 12Letrozole 12Albumin-Bound Paclitaxel 12Drug Therapy 11fluzoparib 10fludarabine 10Specimen Handling 10Magnetic Resonance Spectroscopy 10Biopsy 10durvalumab 9Nivolumab 9pazopanib 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Ovarian Neoplasms × angiotensin I (1-7) × Clear all
NCT00771810 2017-11-13

Study of Drug to Reduce Thrombocytopenia in Patients Receiving Chemo for Ovarian, Fallopian Tube or Peritoneal Cancer

Tarix Pharmaceuticals

Phase 2 Completed
34 enrolled 19 charts
Classical hematologyGynecologic

Cytopenia, Anemia, Lymphopenia, Neutropenia, Ovarian Neoplasms, Thrombocytopenia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡